NCT01515306 - A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2012

Primary Completion Date

March 20, 2013

Study Completion Date

February 22, 2021

Conditions

Malignant Solid Tumor

Interventions

BIOLOGICAL

ramucirumab (IMC-1121B)

ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.

DRUG

paclitaxel

paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.

Trial Locations (6)

19111

ImClone Investigational Site, Philadelphia

44195

ImClone Investigational Site, Cleveland

48109

ImClone Investigational Site, Ann Arbor

48202

ImClone Investigational Site, Detroit

98109

ImClone Investigational Site, Seattle

08901

ImClone Investigational Site, New Brunswick

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY